Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

but serial echocardiograms did not show restrictive cardiomyopathy or progression of the ventricular wall or septal thickness, ruling out cardiac amyloid involvement. Bone marrow biopsy and fat ...

Despite a sceptical appraisal by FDA reviewers, Alnylam's Onpattro has been recommended for approval as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM) by the regulator's advisors.

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval.

“Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive disease [that] sadly impairs the quality of life, functional capacity and health status of patients, as described by ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.

Tafamidis and tafamidis meglumine may help treat transthyretin amyloid cardiomyopathy (ATTR-CM). Medicare Part D prescription drug plans may cover the cost of these medications. Transthyretin ...

This would be with respect to the advancement of nexiguran ziclumeran [nex-z] as a treatment option for patients with ATTR Amyloidosis with cardiomyopathy [ATTR-CM]. The use of this drug ...

Impact of Baseline Heart Failure Severity on Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial: A Subgroup Analysis An exploratory ...

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...